$8.84
5.24% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US0050831009
Symbol
ACTU
Sector
Industry

Actuate Therapeutics Stock price

$8.84
+0.16 1.84% 1M
+0.23 2.67% 6M
+0.23 2.67% YTD
+0.23 2.67% 1Y
+0.23 2.67% 3Y
+0.23 2.67% 5Y
+0.23 2.67% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.44 5.24%
ISIN
US0050831009
Symbol
ACTU
Sector
Industry

Key metrics

Market capitalization $172.66m
Enterprise Value $273.79m
P/B ratio (TTM) P/B ratio 32.22
Cash position $13.52m

Is Actuate Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Actuate Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Actuate Therapeutics:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Actuate Therapeutics:

Buy
100%

Financial data from Actuate Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 1.64 1.64
131% 131%
-
- Research and Development Expense 3.76 3.76
35% 35%
-
-5.39 -5.39
17% 17%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.39 -5.39
17% 17%
-
Net Profit -5.97 -5.97
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Actuate Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Actuate Therapeutics Stock News

Neutral
GlobeNewsWire
12 days ago
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced new positive data from its ongoing and f...
Neutral
GlobeNewsWire
2 months ago
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “ Webinar Wednesd...

Company Profile

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Head office United States
CEO Daniel Schmitt
Website www.actuatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today